<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id>
      <journal-title-group>
        <journal-title>BMC Pulmonary Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2466</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26496968</article-id>
      <article-id pub-id-type="pmc">4619262</article-id>
      <article-id pub-id-type="publisher-id">130</article-id>
      <article-id pub-id-type="doi">10.1186/s12890-015-0130-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary <italic>Mycobacterium avium</italic> complex lesion: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Namkoong</surname>
            <given-names>Ho</given-names>
          </name>
          <address>
            <email>hounamugun@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Tasaka</surname>
            <given-names>Sadatomo</given-names>
          </name>
          <address>
            <phone>+81-3-5363-3793</phone>
            <email>tasaka@cpnet.med.keio.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Akiyama</surname>
            <given-names>Mitsuhiro</given-names>
          </name>
          <address>
            <email>hhhirooo@hotmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yagi</surname>
            <given-names>Kazuma</given-names>
          </name>
          <address>
            <email>kazumayagi1214@yahoo.co.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ishii</surname>
            <given-names>Makoto</given-names>
          </name>
          <address>
            <email>ishii@z6.keio.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Suzuki</surname>
            <given-names>Katsuya</given-names>
          </name>
          <address>
            <email>katsuyas@ta2.so-net.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kohno</surname>
            <given-names>Mitsutomo</given-names>
          </name>
          <address>
            <email>kohno@a3.keio.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hasegawa</surname>
            <given-names>Naoki</given-names>
          </name>
          <address>
            <email>n-hasegawa@z8.keio.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Tsutomu</given-names>
          </name>
          <address>
            <email>tsutake@z5.keio.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Betsuyaku</surname>
            <given-names>Tomoko</given-names>
          </name>
          <address>
            <email>tbetsuyaku@z5.keio.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582 Japan </aff>
        <aff id="Aff2"><label/>Division of Rheumatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan </aff>
        <aff id="Aff3"><label/>Division of General Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan </aff>
        <aff id="Aff4"><label/>Center for Infectious Diseases and Infection Control, Keio University School of Medicine, Tokyo, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>23</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>126</elocation-id>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Namkoong et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Biological agents inhibiting TNF-&#x3B1; and other molecules involved in inflammatory cascade have been increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can be used safely in a patient with an underlying chronic infectious disease.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6 receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with pulmonary <italic>Mycobacterium avium</italic> complex (MAC) infection, and high-resolution computed tomography (HRCT) showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has not been observed for more than 1&#xA0;year.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches may enable introduction or resumption of biological agents.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Biological agents</kwd>
        <kwd><italic>Mycobacterium avium</italic> complex (MAC)</kwd>
        <kwd>Resection</kwd>
        <kwd>Rheumatoid arthritis</kwd>
        <kwd>Tocilizumab</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Various types of biological agents such as infliximab and tocilizumab (TCZ) have been increasingly used to treat rheumatoid arthritis (RA) because of their effectiveness [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. RA patients are often complicated by pulmonary lesion including interstitial pneumonia and bronchiectasis that is vulnerable to infection [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. According to the recent systematic review, both standard-dose and high-dose biological agents are associated with the increased risk of serious infections, compared with traditional disease-modifying anti-rheumatic drugs (DMARDs) [<xref ref-type="bibr" rid="CR5">5</xref>]. With respect to the difference in susceptibility between the classes of biologics, no difference in the risk of infection has been reported between TCZ and others, although the Cochrane review in 2011 reported that abatacept, cytotoxic T lymphocyte antigen 4-immunoglobulin, was significantly less likely to cause infection than infliximab and TCZ [<xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, it has been shown that biological agents are associated with a significant increase in mycobacterial diseases [<xref ref-type="bibr" rid="CR7">7</xref>]. Concerning the types of mycobacterial diseases, Winthrop and coworkers reported that nontuberculous mycobacteria (NTM) infections were more common than tuberculosis among patients receiving biologics [<xref ref-type="bibr" rid="CR8">8</xref>]. Especially in Japan, the most recent nationwide survey revealed that the incidence rate of pulmonary NTM disease (14.7 persons per 100,000 person-years) may exceed that of tuberculosis in general population, and that Japan may have one of the highest incidence rates of pulmonary NTM disease worldwide [<xref ref-type="bibr" rid="CR9">9</xref>]. Whereas tuberculosis can usually be controlled by the standard chemotherapy, no effective chemotherapy has been established against <italic>Mycobacterium avium</italic> complex (MAC), leading to aggravation of MAC infection during immunosuppressive therapy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. According to Japanese postmarketing surveillance of TCZ in RA patients, the incidence of NTM infections (0.22&#xA0;%) is higher than that of tuberculosis (0.05&#xA0;%) [<xref ref-type="bibr" rid="CR12">12</xref>]. Although many of RA patients have underlying pulmonary lesions and other risk factors for potential NTM infection, it is still controversial whether biological agents can be a risk of exacerbation of pre-existing pulmonary NTM disease [<xref ref-type="bibr" rid="CR11">11</xref>]. Consequently, a strategy for the management of NTM in RA patients subjected to treatment with biologics remains to be established.</p>
      <p>In this report, a case of pulmonary MAC disease in an RA patient who successfully resumed TCZ after the resection of a single cavitary lesion is presented. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially in those with a fibrocavitary lesion, a multimodality approach for MAC may enable introduction or resumption of biological agents.&#xA0;This report is in compliance with the Helsinki Declaration.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>In September 2013, a 63-year-old woman was referred to our outpatient clinic due to hemoptysis and a pulmonary lesion on high-resolution computed tomography (HRCT). Her height was 165.0&#xA0;cm and body weight was 46.0&#xA0;kg. The patient never smoked but had a medical history of Crohn&#x2019;s disease, which remained in remission, and RA that was diagnosed in 2010 according to the criteria of the American College of Rheumatology. She had been treated with prednisolone (PSL) (5&#xA0;mg/day) and methotrexate (12&#xA0;mg/week). Because the disease activity was not properly controlled with these medications, methotrexate was stopped and 360&#xA0;mg of TCZ was administered intravenously once every 4&#xA0;weeks from October 2011. At this time, the visual analogue scale (VAS) was 37&#xA0;mm and the disease activity score (DAS) 28&#x2013;C-reactive protein (CRP) was 3.81. When TCZ was introduced, her chest radiograph was normal (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>), but HRCT showed a small nodular shadow in the right upper lobe of the lung (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Although the patient had no respiratory symptoms with no pathogenic bacteria isolated from the sputum, she was prescribed 400&#xA0;mg/day clarithromycin (CAM) as a monotherapy before her referral to our department. Two years after the initiation of TCZ, she was admitted for hemoptysis, and a chest radiograph showed infiltration and cavity formation in the right upper lobe (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). HRCT also showed consolidation, cavity formation, bronchiectasis, and centrilobular nodules in the right upper lobe (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>). When admitted, her body temperature was 36.4&#xA0;&#xB0;C. Coarse crackles were auscultated over the right upper lung field and joint pain was positive in her left wrist, right elbow, and metatarsophalangeal joints of the right third and fourth toes. There were no abnormal findings on complete blood counts and biochemistry tests except for mild leukocytopenia (white blood cells, 3300/&#x3BC;L) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). The anti-glycopeptidolipid core IgA antibody was positive (2.44&#xA0;U/mL), and the QuantiFERON&#xAE; TB Gold test was negative. Pulmonary MAC disease was diagnosed because the sputum culture was positive for MAC twice. A Broth MIC&#xAE; NTM showed that the isolated MAC was sensitive to CAM (minimum inhibitory concentration, 1&#xA0;&#x3BC;g/mL) despite 2-year monotherapy with CAM. Combination chemotherapy with 800&#xA0;mg/day of CAM, 450&#xA0;mg/day of rifampicin (RFP), 500&#xA0;mg/day of ethambutol (EB), and thrice weekly intravenous amikacin (600&#xA0;mg/per dose) were started. Because TCZ might have contributed to the exacerbation of the pulmonary MAC disease, TCZ therapy was discontinued after the diagnosis of pulmonary MAC disease. In addition, PSL was tapered to 2&#xA0;mg/day, and nonsteroidal anti-inflammatory drugs were started for RA. At this time, the disease activity of her RA was relatively stable (VAS, 6&#xA0;mm; DAS 28-CRP, 1.99).<fig id="Fig1"><label>Fig. 1</label><caption><p>Serial changes on chest X-ray and chest computed tomography findings. <bold>a</bold> Chest X-ray taken immediately before starting tocilizumab (TCZ), showing subtle nodular infiltrates. <bold>b</bold> CT scan taken immediately before starting TCZ, showing a small nodular shadow in the right upper lobe (<italic>arrowhead</italic>). <bold>c</bold> Chest X-ray taken when the patient developed hemoptysis 2&#xA0;years after starting TCZ, showing infiltration and cavity formation in the right upper lung field (<italic>arrowhead</italic>). <bold>d</bold> CT scan taken when the patient developed hemoptysis 2&#xA0;years after starting TCZ, showing consolidation, cavity formation, bronchiectasis, and centrilobular nodules in the right upper lobe (<italic>arrowhead</italic>)</p></caption><graphic xlink:href="12890_2015_130_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Laboratory findings on admission</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Complete blood count</th></tr></thead><tbody><tr><td>&#x2003;White blood cells</td><td>3300/&#x3BC;L</td></tr><tr><td>&#x2003;&#x2003;Band cells&#x2009;+&#x2009;Seg cells</td><td>54.1&#xA0;%</td></tr><tr><td>&#x2003;&#x2003;Lymphocytes</td><td>32.7&#xA0;%</td></tr><tr><td>&#x2003;&#x2003;Monocytes</td><td>8.1&#xA0;%</td></tr><tr><td>&#x2003;&#x2003;Eosinophil granulocytes</td><td>4.5&#xA0;%</td></tr><tr><td>&#x2003;&#x2003;Basophil granulocytes</td><td>0.6&#xA0;%</td></tr><tr><td>&#x2003;Hemoglobin</td><td>13.8&#xA0;g/dL</td></tr><tr><td>&#x2003;Mean corpuscular volume</td><td>94/fL</td></tr><tr><td>&#x2003;Platelets</td><td>182&#x2009;&#xD7;&#x2009;10<sup>3</sup> /&#x3BC;L</td></tr><tr><td colspan="2">Biochemistry</td></tr><tr><td>&#x2003;Total protein</td><td>6.4&#xA0;g/dL</td></tr><tr><td>&#x2003;Albumin</td><td>4.2&#xA0;g/dL</td></tr><tr><td>&#x2003;Total bilirubin</td><td>0.7&#xA0;mg/dL</td></tr><tr><td>&#x2003;Glutamic oxaloacetic transaminase</td><td>20&#xA0;IU/L</td></tr><tr><td>&#x2003;Glutamic pyruvic transaminase</td><td>14&#xA0;IU/L</td></tr><tr><td>&#x2003;Lactate dehydrogenase</td><td>180&#xA0;IU/L</td></tr><tr><td>&#x2003;Urea nitrogen</td><td>11.2&#xA0;mg/dL</td></tr><tr><td>&#x2003;Creatinine</td><td>0.64&#xA0;mg/dL</td></tr><tr><td>&#x2003;Sodium</td><td>143.2&#xA0;mEq/L</td></tr><tr><td>&#x2003;Potassium</td><td>3.9&#xA0;mEq/L</td></tr><tr><td>&#x2003;Chloride</td><td>109&#xA0;mEq/L</td></tr><tr><td>&#x2003;Alkaline phosphatase</td><td>197&#xA0;IU/L</td></tr><tr><td>&#x2003;Gamma-glutamyl transferase</td><td>13&#xA0;IU/L</td></tr><tr><td colspan="2">Serological studies</td></tr><tr><td>&#x2003;C-reactive protein</td><td>0.01&#xA0;mg/dL</td></tr><tr><td>&#x2003;Matrix metalloproteinase 3</td><td>42.2&#xA0;ng/mL</td></tr><tr><td>&#x2003;&#x3B2;-D-glucan</td><td>&lt;3.0&#xA0;pg/mL</td></tr><tr><td>&#x2003;
<italic>Aspergillus</italic> antigen</td><td>0.0 COI</td></tr><tr><td>&#x2003;
<italic>Cryptococcus</italic> antigen</td><td>0.0 COI</td></tr><tr><td>&#x2003;QuantiFERON&#xAE; TB Gold test</td><td>Negative</td></tr><tr><td>&#x2003;Anti-glycopeptidolipid core IgA antibody</td><td>2.44 U/mL</td></tr></tbody></table></table-wrap></p>
      <p>Although 3&#xA0;months of anti-MAC treatment improved the consolidation and centrilobular nodules, the cavitary lesion and bronchiectasis were still significant on chest X-ray and HRCT (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a, b</xref>). Her right upper lobe was resected (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>), since her lesion was limited to a single lobe and the cavitary lesion seemed refractory to drug therapy. As expected, tissue culture of the resected specimen tested positive for MAC. Although her pulmonary MAC lesion was totally removed with the operation and microbiological examinations remained negative, CAM, RFP, and EB were continued to prevent a relapse of MAC pulmonary disease. Because she reported deterioration of her joint symptoms around the time of the operation (VAS, 38&#xA0;mm; DAS 28-CRP, 4.07), TCZ was resumed 1&#xA0;month after resection.<fig id="Fig2"><label>Fig. 2</label><caption><p>Serial changes on chest X-ray and chest computed tomography findings. <bold>a</bold> Chest X-ray taken 3&#xA0;months after chemotherapy against <italic>Mycobacterium avium</italic> complex (MAC), showing improved infiltration (<italic>arrowhead</italic>). <bold>b</bold> CT scan taken 3&#xA0;months after chemotherapy against MAC, showing diminished consolidation and centrilobular nodules in the right upper lobe (<italic>arrowhead</italic>). <bold>c</bold> Chest X-ray taken 1&#xA0;year after resuming TCZ, showing no abnormal findings other than the postoperative findings after the right upper lobectomy. <bold>d</bold> CT scan taken 1&#xA0;year after resuming TCZ, showing no postoperative findings of right upper lobectomy</p></caption><graphic xlink:href="12890_2015_130_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Photograph and photomicrographs of the lung. <bold>a</bold> Photograph of a cross-sectional specimen from the resected right upper lung. <bold>b</bold> Photomicrographs showing an epithelioid granuloma with necrosis (bar, 5&#xA0;mm). <bold>c</bold> Photomicrographs showing an epithelioid granuloma with necrosis (bar, 500&#xA0;&#x3BC;m). <bold>d</bold> Photomicrograph showing Langhans giant cells (<italic>arrowheads</italic>) and epithelioid cells (<italic>arrow</italic>) (bar, 100&#xA0;&#x3BC;m)</p></caption><graphic xlink:href="12890_2015_130_Fig3_HTML" id="MO3"/></fig></p>
      <p>Two months after the restarting of TCZ, her joint symptoms had totally improved; the VAS improved from 38 to 3&#xA0;mm, and DAS 28-CRP improved from 4.07 to 1.06. In terms of the pulmonary MAC disease, no new lesion was found by HRCT at 1&#xA0;year after the resumption of TCZ (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c, d</xref>).</p>
    </sec>
    <sec id="Sec3">
      <title>Conclusions</title>
      <p>MAC is one of the most common opportunistic pathogens in RA patients on biological agents [<xref ref-type="bibr" rid="CR13">13</xref>]. Although most immunocompetent patients with MAC infection maintain a stable clinical course for years, immunocompromised patients often show rapid progression of the disease. Previous MAC infections in RA patients are a particularly controversial issue, because the aggravation of MAC infection requires abandoning effective treatment with biological agents [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, some case reports and the new joint statement published by the Japanese Respiratory Society (JRS), Japan College of Rheumatology (JCR), and Japanese Society for Tuberculosis (JSTB) in 2014 proposed that, in certain RA patients with pulmonary MAC disease, biological agents can be safely used in combination with chemotherapy for pulmonary MAC disease [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In the case series by Mori and colleagues, anti-TNF agents could be safely reintroduced in seven patients without exacerbation of the MAC infection [<xref ref-type="bibr" rid="CR14">14</xref>]. Nakahara and coworkers also described a case of successful reintroduction of TCZ without aggravation of MAC infection under the standard chemotherapy [<xref ref-type="bibr" rid="CR15">15</xref>]. However, there has been no report of surgical resection of MAC lesion followed by successful reintroduction of biologics. In this regard, this is the first case report which indicates that biological agents might be safely resumed after surgery.</p>
      <p>In this case, HRCT taken before the initiation of TCZ treatment showed small nodular opacity in the right upper lobe, suggesting pre-existing MAC disease. Since monotherapy with macrolides can induce macrolide-resistance, it is not an appropriate treatment in the presence of MAC disease [<xref ref-type="bibr" rid="CR17">17</xref>]. Therefore, bronchoscopy should have been performed to make a diagnosis of pulmonary MAC disease so that combination chemotherapy could be introduced at an earlier time point.</p>
      <p>After the exacerbation of pulmonary MAC disease, HRCT showed consolidation, cavity formation, bronchiectasis, and centrilobular nodules that were localized only in the right upper lobe. According to the JSTB statement about the resection of pulmonary NTM disease, a single cavity lesion is a good candidate for surgery to suppress the activity of pulmonary NTM disease [<xref ref-type="bibr" rid="CR18">18</xref>]. From this standpoint, our approach to eradicating MAC lesions was appropriate.</p>
      <p>According to the recent joint statement, patients with NTM are in principle prohibited from using biological agents [<xref ref-type="bibr" rid="CR18">18</xref>]. The statement also mentioned that using biological agents could be considered with full evaluation of the risk and benefit, only in the following cases: (i) the causative pathogen is MAC; (ii) the radiographic features are of the nodular/bronchiectatic type; (iii) the existing pulmonary lesion is limited; (iv) the patient&#x2019;s general performance status is good; (v) chemotherapy against NTM could be given in the long term with a good treatment response; and (vi) biological agents are strongly needed because of the high disease activity of RA. It also stated that using biologics in those with a fibrocavitary lesion of NTM is a contraindication [<xref ref-type="bibr" rid="CR18">18</xref>]. The present case indicated the possibility of safe reintroduction of biological agents after resection, even in cases with a fibrocavitary lesion, when the cavitary lesion is localized in a single lobe. Since no difference in the risk of infection has been reported between TCZ and other biological agents [<xref ref-type="bibr" rid="CR7">7</xref>], we considered that this strategy might be applied not only for TCZ but also for other biologics.</p>
      <p>One of the discussion points is the validity of surgical resection against MAC disease. In this case, her hemoptysis disappeared after 3&#xA0;months of chemotherapy and the infiltrates around the cavity were also resolved. However, the cavitary lesion, which could discharge mycobacteria and might predispose the patient to later recurrence, was not changed. In general, the cavitary lesion of MAC patients is difficult to be resolved by chemotherapy alone and is good indication for surgical resection [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Especially for this patient with high disease activity of RA, we thought it reasonable to remove the cavitary lesion surgically in order to resume biological agents.</p>
      <p>Another discussion point is the duration of concurrent chemotherapy against MAC as well as perioperative chemotherapy. It was possible to discontinue the chemotherapy against MAC when the MAC lesion was totally removed by surgery. However, it was assumed that chemotherapy should be continued to prevent the growth of minimal MAC lesion, which was undetectable by HRCT. A retrospective review of pulmonary resection in patients with NTM showed that postoperative chemotherapy might contribute to decreasing the relapse rate [<xref ref-type="bibr" rid="CR20">20</xref>]. The JSTB statement about the resection of pulmonary NTM disease also recommended postoperative adjuvant chemotherapy [<xref ref-type="bibr" rid="CR18">18</xref>]. In any case, careful follow-up to monitor the re-emergence of the MAC lesion or other opportunistic infections is needed as long as the patient is receiving biological agents.</p>
      <p>In conclusion, an RA case for which TCZ was safely reintroduced after resection of the pulmonary MAC lesion was presented. Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially with a fibrocavitary lesion, a multimodality approach for MAC may be considered in order to use biological agents safely.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>RA</term>
          <def>
            <p>Rheumatoid arthritis</p>
          </def>
        </def-item>
        <def-item>
          <term>TCZ</term>
          <def>
            <p>Tocilizumab</p>
          </def>
        </def-item>
        <def-item>
          <term>MAC</term>
          <def>
            <p>Mycobacterium avium complex</p>
          </def>
        </def-item>
        <def-item>
          <term>HRCT</term>
          <def>
            <p>High-resolution computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>DMARDs</term>
          <def>
            <p>Disease-modifying anti-rheumatic drugs</p>
          </def>
        </def-item>
        <def-item>
          <term>NTM</term>
          <def>
            <p>Nontuberculous mycobacteria</p>
          </def>
        </def-item>
        <def-item>
          <term>PSL</term>
          <def>
            <p>Prednisolone</p>
          </def>
        </def-item>
        <def-item>
          <term>VAS</term>
          <def>
            <p>Visual analogue scale</p>
          </def>
        </def-item>
        <def-item>
          <term>DAS</term>
          <def>
            <p>Disease activity score</p>
          </def>
        </def-item>
        <def-item>
          <term>CRP</term>
          <def>
            <p>C-reactive protein</p>
          </def>
        </def-item>
        <def-item>
          <term>CAM</term>
          <def>
            <p>Clarithromycin</p>
          </def>
        </def-item>
        <def-item>
          <term>RFP</term>
          <def>
            <p>Rifampicin</p>
          </def>
        </def-item>
        <def-item>
          <term>EB</term>
          <def>
            <p>Ethambutol</p>
          </def>
        </def-item>
        <def-item>
          <term>JRS</term>
          <def>
            <p>Japanese Respiratory Society</p>
          </def>
        </def-item>
        <def-item>
          <term>JCR</term>
          <def>
            <p>Japan College of Rheumatology</p>
          </def>
        </def-item>
        <def-item>
          <term>JSTB</term>
          <def>
            <p>Japanese Society for Tuberculosis</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors state that they have no conflict of interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>HN and ST drafted the manuscript and were responsible for clinical care of the patients. MA, KY, MI, KS, MK, NH, TT, and TB were responsible for clinical care of the patients. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>No funding to declare.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takeuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kameda</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>The Japanese experience with biologic therapies for rheumatoid arthritis</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2010</year>
          <volume>6</volume>
          <issue>11</issue>
          <fpage>644</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2010.154</pub-id>
          <pub-id pub-id-type="pmid">20877307</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woodrick</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Ruderman</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Safety of biologic therapy in rheumatoid arthritis</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>11</issue>
          <fpage>639</fpage>
          <lpage>652</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2011.145</pub-id>
          <pub-id pub-id-type="pmid">21989284</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hirani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Matteson</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>WG</given-names>
            </name>
          </person-group>
          <article-title>The safety of biologic therapies in RA-associated interstitial lung disease</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2014</year>
          <volume>10</volume>
          <issue>5</issue>
          <fpage>284</fpage>
          <lpage>294</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2013.197</pub-id>
          <pub-id pub-id-type="pmid">24366321</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furst</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>The risk of infections with biologic therapies for rheumatoid arthritis</article-title>
          <source>Semin Arthritis Rheum</source>
          <year>2010</year>
          <volume>39</volume>
          <issue>5</issue>
          <fpage>327</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="doi">10.1016/j.semarthrit.2008.10.002</pub-id>
          <pub-id pub-id-type="pmid">19117595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Cameron</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Noorbaloochi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cullis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tucker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ghogomu</surname>
              <given-names>ET</given-names>
            </name>
            <name>
              <surname>Coyle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clifford</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tugwell</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis</article-title>
          <source>Lancet</source>
          <year>2015</year>
          <volume>386</volume>
          <issue>9990</issue>
          <fpage>258</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61704-9</pub-id>
          <pub-id pub-id-type="pmid">25975452</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Christensen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tanjong Ghogomu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Maxwell</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Macdonald</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Filippini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Skoetz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>LC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Adverse effects of biologics: a network meta-analysis and Cochrane overview</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2011</year>
          <volume>2</volume>
          <fpage>CD008794</fpage>
          <pub-id pub-id-type="pmid">21328309</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kourbeti</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Ziakas</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Mylonakis</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis</article-title>
          <source>Clin Infect Dis</source>
          <year>2014</year>
          <volume>58</volume>
          <issue>12</issue>
          <fpage>1649</fpage>
          <lpage>1657</lpage>
          <pub-id pub-id-type="doi">10.1093/cid/ciu185</pub-id>
          <pub-id pub-id-type="pmid">24647016</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winthrop</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Yamashita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Beekmann</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Polgreen</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network</article-title>
          <source>Clin Infect Dis</source>
          <year>2008</year>
          <volume>46</volume>
          <issue>11</issue>
          <fpage>1738</fpage>
          <lpage>1740</lpage>
          <pub-id pub-id-type="doi">10.1086/587989</pub-id>
          <pub-id pub-id-type="pmid">18419421</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">Namkoong H, Kurashima A, Morimoto K,&#xB7;Hoshino Y, Hasegawa N, Manabu A,&#xB7;Mitarai S: Nationwide Survey on the Epidemiology of Pulmonary Nontuberculous Mycobacterial in Japan. The annual meeting of American Thoracic Society 2015/05.</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henkle</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Winthrop</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
          <article-title>Nontuberculous mycobacteria infections in immunosuppressed hosts</article-title>
          <source>Clin Chest Med</source>
          <year>2015</year>
          <volume>36</volume>
          <issue>1</issue>
          <fpage>91</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccm.2014.11.002</pub-id>
          <pub-id pub-id-type="pmid">25676522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Winthrop</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Iseman</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy</article-title>
          <source>Nat Rev Rheumatol</source>
          <year>2013</year>
          <volume>9</volume>
          <issue>9</issue>
          <fpage>524</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="doi">10.1038/nrrheum.2013.82</pub-id>
          <pub-id pub-id-type="pmid">23797309</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakajima</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Origasa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tomobe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Totsuka</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan</article-title>
          <source>J Rheumatol</source>
          <year>2015</year>
          <volume>42</volume>
          <issue>8</issue>
          <fpage>1368</fpage>
          <lpage>1375</lpage>
          <pub-id pub-id-type="doi">10.3899/jrheum.141210</pub-id>
          <pub-id pub-id-type="pmid">26034149</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Ingen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Boeree</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Dekhuijzen</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>van Soolingen</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Mycobacterial disease in patients with rheumatic disease</article-title>
          <source>Nat Clin Pract Rheumatol</source>
          <year>2008</year>
          <volume>4</volume>
          <issue>12</issue>
          <fpage>649</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.1038/ncprheum0949</pub-id>
          <pub-id pub-id-type="pmid">19037226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tokuda</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sakai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Johkoh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mimori</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nishimoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tasaka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hatta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsushima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kaise</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan</article-title>
          <source>Mod Rheumatol</source>
          <year>2012</year>
          <volume>22</volume>
          <issue>5</issue>
          <fpage>727</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="doi">10.3109/s10165-011-0577-6</pub-id>
          <pub-id pub-id-type="pmid">22207481</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nakahara</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kamide</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hamano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hosokawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nishide</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawamoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fusama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Higa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kuroiwa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment</article-title>
          <source>Mod Rheumatol</source>
          <year>2011</year>
          <volume>21</volume>
          <issue>6</issue>
          <fpage>655</fpage>
          <lpage>659</lpage>
          <pub-id pub-id-type="doi">10.3109/s10165-011-0448-1</pub-id>
          <pub-id pub-id-type="pmid">21484291</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Biological agents and pulmonary diseases - the statement of the management - the Japanese Respiratory Society, the Japan college of Rheumatology and the Japanese Society for Tuberculosis. (in Japanese) 2014.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Griffith</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Brown-Elliott</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Langsjoen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Girard</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nelson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Caccitolo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2006</year>
          <volume>174</volume>
          <issue>8</issue>
          <fpage>928</fpage>
          <lpage>934</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200603-450OC</pub-id>
          <pub-id pub-id-type="pmid">16858014</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>The Nontuberculous Mycobacteria Committee of Japanese Society for Tuberculosis</collab>
          </person-group>
          <article-title>The statement of surgery against <italic>Mycobacterium avium</italic> comlex lung disease</article-title>
          <source>Kekkaku</source>
          <year>2008</year>
          <volume>83</volume>
          <issue>12</issue>
          <fpage>527</fpage>
          <lpage>528</lpage>
          <pub-id pub-id-type="pmid">18792457</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Weyant</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Surgical treatment of atypical mycobacterial infections</article-title>
          <source>Thorac Surg Clin</source>
          <year>2012</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>277</fpage>
          <lpage>285</lpage>
          <pub-id pub-id-type="doi">10.1016/j.thorsurg.2012.05.004</pub-id>
          <pub-id pub-id-type="pmid">22789593</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shiraishi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Katsuragi</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kita</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hyogotani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Shimoda</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Adjuvant surgical treatment of nontuberculous mycobacterial lung disease</article-title>
          <source>Ann Thorac Surg</source>
          <year>2013</year>
          <volume>96</volume>
          <issue>1</issue>
          <fpage>287</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.03.008</pub-id>
          <pub-id pub-id-type="pmid">23618520</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
